​

Insulet (PODD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PODD Stock Forecast

Insulet (PODD) stock forecast, based on 40 Wall Street analysts, predicts a 12-month average price target of $322.00, with a high of $322.00 and a low of $322.00. This represents a 6.05% increase from the last price of $303.62.

$150 $190 $230 $270 $310 $350 High: $322 Avg: $322 Low: $322 Last Closed Price: $303.62

PODD Stock Rating

Insulet stock's rating consensus is Buy, based on 40 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (70.00%), 10 Hold (25.00%), 2 Sell (5.00%), and 0 Strong Sell (0.00%).

Buy
Total 40 0 2 10 28 Strong Sell Sell Hold Buy Strong Buy

PODD Price Target Upside V Benchmarks

TypeNameUpside
StockInsulet6.05%
SectorHealthcare Stocks 24.81%
IndustryMedical Device Stocks16.21%

Price Target Trends

1M3M12M
# Anlaysts-19
Avg Price Target-$322.00$267.78
Last Closing Price$303.62$303.62$303.62
Upside/Downside-6.05%-11.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 257142-124
May, 256135--24
Apr, 256144--24
Mar, 255144--23
Feb, 255144--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 28, 2025Wells Fargo$322.00$259.5224.08%6.05%
Nov 08, 2024Marie ThibaultBTIG$270.00$268.960.39%-11.07%
Nov 05, 2024Lee HambrightBernstein$300.00$241.3224.32%-1.19%
Oct 14, 2024Jayson BedfordRaymond James$260.00$231.6112.26%-14.37%
Sep 17, 2024Matt O'BrienPiper Sandler$285.00$233.8921.85%-6.13%
Aug 27, 2024Matt O'BrienPiper Sandler$230.00$193.5218.85%-24.25%
Aug 27, 2024Steven LichtmanOppenheimer$233.00$193.5420.39%-23.26%
Aug 27, 2024Matthew TaylorJefferies$260.00$193.5434.34%-14.37%
Aug 09, 2024Marie ThibaultBTIG$250.00$199.7925.13%-17.66%
May 13, 2024Matt MiksicBarclays$200.00$165.9020.55%-34.13%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 27, 2025Raymond JamesOutperformOutperformhold
May 22, 2025CitigroupBuyBuyhold
May 16, 2025BernsteinOutperformOutperformhold
May 13, 2025Wolfe ResearchBuyOutperformupgrade
Mar 05, 2025RBC CapitalOutperforminitialise
Jan 08, 2025BernsteinOutperformOutperformhold
Jan 03, 2025Cowen & Co.BuyBuyhold
Dec 30, 2024BTIGBuyBuyhold
Dec 11, 2024CitigroupBuyBuyhold
Dec 11, 2024CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.11$0.25$0.07$2.96$5.97----
Avg Forecast$0.32$0.13$0.42$1.99$3.21$3.93$4.95$5.96$7.30
High Forecast$0.33$0.13$0.43$2.08$3.36$4.30$5.68$6.79$7.55
Low Forecast$0.32$0.13$0.41$1.86$3.11$3.71$3.58$4.76$7.08
Surprise %-65.63%92.31%-83.33%48.74%85.98%----

Revenue Forecast

$500M $1B $2B $3B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$904.40M$1.10B$1.31B$1.70B$2.07B----
Avg Forecast$891.32M$1.09B$1.27B$1.65B$2.06B$2.43B$2.86B$3.32B$3.75B
High Forecast$909.66M$1.11B$1.30B$1.69B$2.11B$2.49B$2.86B$3.35B$3.85B
Low Forecast$876.78M$1.07B$1.24B$1.64B$2.05B$2.40B$2.85B$3.28B$3.67B
Surprise %1.47%0.66%2.88%2.96%0.71%----

Net Income Forecast

$-150M $0 $150M $300M $450M $600M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.80M$16.80M$4.60M$206.30M$418.30M----
Avg Forecast$23.92M$4.65M$-70.49M$206.30M$238.15M$289.34M$368.31M$434.07M$537.52M
High Forecast$24.56M$17.25M$-30.76M$322.59M$247.32M$316.29M$418.31M$499.77M$555.71M
Low Forecast$23.41M$-7.94M$-110.23M$90.01M$228.97M$273.53M$263.30M$350.38M$521.49M
Surprise %-71.57%261.00%-106.53%-75.65%----

PODD Forecast FAQ

Is Insulet stock a buy?

Insulet stock has a consensus rating of Buy, based on 40 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 10 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Insulet is a favorable investment for most analysts.

What is Insulet's price target?

Insulet's price target, set by 40 Wall Street analysts, averages $322 over the next 12 months. The price target range spans from $322 at the low end to $322 at the high end, suggesting a potential 6.05% change from the previous closing price of $303.62.

How does Insulet stock forecast compare to its benchmarks?

Insulet's stock forecast shows a 6.05% upside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the medical device stocks industry (16.21%).

What is the breakdown of analyst ratings for Insulet over the past three months?

  • June 2025: 29.17% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 4.17% Strong Sell.
  • May 2025: 25.00% Strong Buy, 54.17% Buy, 20.83% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 25.00% Strong Buy, 58.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Insulet’s EPS forecast?

Insulet's average annual EPS forecast for its fiscal year ending in December 2025 is $3.93, marking a -34.17% decrease from the reported $5.97 in 2024. Estimates for the following years are $4.95 in 2026, $5.96 in 2027, and $7.3 in 2028.

What is Insulet’s revenue forecast?

Insulet's average annual revenue forecast for its fiscal year ending in December 2025 is $2.43B, reflecting a 17.42% increase from the reported $2.07B in 2024. The forecast for 2026 is $2.86B, followed by $3.32B for 2027, and $3.75B for 2028.

What is Insulet’s net income forecast?

Insulet's net income forecast for the fiscal year ending in December 2025 stands at $289.34M, representing a -30.83% decrease from the reported $418.3M in 2024. Projections indicate $368.31M in 2026, $434.07M in 2027, and $537.52M in 2028.